



Project Manager  
Office of Complementary Medicine  
Therapeutic Goods Administration  
PO Box 100  
Woden ACT 2606  
[ocm@tga.gov.au](mailto:ocm@tga.gov.au)

**Bayer submission on the consultation document  
“Evidence required to support indications for listed  
medicines (excluding sunscreens and disinfectants)  
Version 2.0 August 2012”**

Dear Sir/Madam,

The consultation document was released on 27th August and the consultation period closed on 22nd October (i.e. a review period of only 40 working days). This is not inadequate to prepare a meaningful response to the 97 page consultation document. A meaningful response requires a thorough review of the proposal and an accurate identification of all the issues. On this point we note that the consultation document is extremely detailed, deals with a complex topic and proposes significant changes.

Consequently, Bayer’s response is incomplete.

Bayer supports the submission made by the Australian Self-Medication Industry (ASMI).

We thank you for the opportunity to provide comments on this consultation document and we look forward to further consultation on the next draft in the near future.

Yours sincerely

A handwritten signature in black ink, appearing to read "Lynda".

Lynda McFarlane  
Regulatory and Medical Information Manager  
Bayer Limited

22 October 2012

Bayer Australia Limited  
ABN 22 000 138 714

875 Pacific Highway  
Pymble, New South Wales 2073  
Sydney, Australia

Postal Address  
PO Box 903  
Pymble, New South Wales 2073  
Sydney, Australia

Telephone: +61 2 9391 6000  
Facsimile: +61 2 9391 3311  
[www.bayer.com.au](http://www.bayer.com.au)